Quest Diagnostics Incorporated [DGX] has traded in a range of $73.02 to $131.81 in the last 1 year. As of this writing, the stock is at $121.00, up 2.43%. To check whether the stock’s short-term amount has a thrust, its good to check stock’s recent movement. Over the last week, DGX shares are 1.60% up with the monthly amount drift of 3.13% and seems well in a long time frame.
On 15, October 2020, Fentanyl and Heroin Misuse Skyrockets During COVID-19 Pandemic, Finds Quest Diagnostics Health Trends Study. According to news published on Yahoo Finance, Largest nationally representative study based on laboratory data shows double-digit increases in mixing of fentanyl with amphetamines and cocaine.
Analyst Birdseye View:
The most recent analyst activity for Quest Diagnostics Incorporated [NYSE:DGX] stock was on July 14, 2020, when it was Upgrade with a Buy rating from BofA Securities, which also raised its 12-month price target on the stock to $142. Before that, on July 29, 2020, KeyBanc Capital Markets Recapitulated an Overweight rating and elevated its amount target to $144. On June 09, 2020, Wells Fargo Upgrade an Equal weight rating and boosted its price target on this stock from $90 to $120. On June 02, 2020, Deutsche Bank Upgrade a Buy rating and increased its price target to $140. On April 28, 2020, Morgan Stanley Upgrade an Overweight rating and increased its price target to $139. On April 27, 2020, Wolfe Research Upgrade a Peer perform rating. On April 27, 2020, Citigroup Upgrade a Buy rating and boosted its target amount on this stock from $113 to $130. Morgan Stanley elevated its amount target by recapitulating a higher weight for this stock.
In the past 52 weeks of trading, this stock has oscillated between a low of $73.02 and a peak of $131.81. Right now, the middling Wall Street analyst 12-month amount mark is $144.00. At the most recent market close, shares of Quest Diagnostics Incorporated [NYSE:DGX] were valued at $121.00. According to the average price forecast, investors can expect a potential return of 3.17%.
Quest Diagnostics Incorporated [NYSE:DGX] most recently reported quarterly sales of 1.83 billion, which represented growth of -6.50%. This publicly-traded organization’s revenue is $164,383 per employee, while its income is $17,766 per employee. This company’s Gross Margin is currently 34.10%, its Operating Margin is 15.10%, its Pretax Margin is +13.93, and its Net Margin is +10.81. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at 7.00, 15.38, 11.89 and 8.95 respectively.
If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 48.98 and the whole liability to whole assets at 42.17. It shows enduring liability to the whole principal at 39.60 and enduring liability to assets at 0.34 while looking for an extended time period.
Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 116.59 points at 1st support level, the second support level is making up to 115.05. But as of 1st resistance point, this stock is sitting at 119.02 and at 119.90 for 2nd resistance point.
Quest Diagnostics Incorporated [DGX] reported its earnings at $1.42 per share in the fiscal quarter closing of 6/29/2020. The Analysts for Wall Street were expecting to report its earnings at $1.41/share signifying the difference of 0.01 and 0.70% surprise value. Comparing the previous quarter ending of 3/30/2020, the stated earnings were $0.94 calling estimates for $0.89/share with the difference of 0.05 depicting the surprise of 5.60%.
Important Ratio’s To Watch
Meanwhile, turning our focus to liquidity, the Current Ratio for Quest Diagnostics Incorporated [NYSE:DGX] is 1.30. Likewise, the Quick ratio is also the same, showing Cash ratio at 0.60. Now if looking for a valuation of this stock’s amount to sales ratio it’s 1.88, it’s amount to book ratio is 2.52 and showing 21.48 of P/E (TTM) ratio.
The most recent insider trade was by PREVOZNIK MICHAEL E, SVP & General Counsel, and it was the sale of 35591.0 shares on Oct 14. Doherty Catherine T., the SVP, Group Exec. Clin. Fran., completed a sale of 58392.0 shares on Sep 02. On Jun 08, GUINAN MARK, Executive Vice President & CFO, completed a sale of 72596.0 shares.